{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T17:49:24Z","timestamp":1720201764209},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There has been controversy over the cardiovascular safety of domperidone, attributable to the lack of a well-designed study as well as inconsistent results. This study aimed to examine the risk of severe domperidone-induced ventricular arrhythmia (VA), compared to mosapride, itopride, or non-use of all three prokinetics, in the general population. We conducted a population-based, self-controlled case series analysis. Enrolled subjects were individuals who were diagnosed with severe VA and were prescribed domperidone, mosapride, or itopride from 2003 to 2013 in the National Health Insurance Service-National Sample Cohort. The incidence rate ratio for severe VA was measured during exposure to prokinetics and compared with unexposed periods and itopride (no-proarrhythmic effect)-exposure periods, as control. A total of 2,817 subjects were included. Domperidone, mosapride, or itopride use was associated with increased risk of severe VA, compared with non-use (adjusted incidence rate ratios (IRR) of 1.342 (95% CI 1.096\u20131.642), 1.350 (95% CI 1.105\u20131.650), and 1.486 (95% CI 1.196\u20131.845), respectively). The risk of severe domperidone-induced VA was lower, compared to that of itopride [adjusted IRR of 0.548 (95% CI 0.345\u20130.870)]. Of the subjects who had been prescribed all three prokinetics, domperidone-exposure was associated with a lower risk of severe VA, compared to itopride-exposure (crude IRR, 0.571; 0.358\u20130.912). Mosapride-exposure did not show IRR difference for severe VA, compared to itopride-exposure. Domperidone, mosapride, or itopride use is associated with an increased risk of severe VA. However, the magnitude of association was modest and domperidone use does not increase further the risk, compared with other prokinetics. <\/jats:p>","DOI":"10.1038\/s41598-020-69053-4","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T10:04:54Z","timestamp":1595412294000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk of domperidone induced severe ventricular arrhythmia"],"prefix":"10.1038","volume":"10","author":[{"given":"Byeong Geun","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeong Chan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang Won","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyunga","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jung","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poong-Lyul","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"69053_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1345\/aph.18003","volume":"33","author":"JA Barone","year":"1999","unstructured":"Barone, J. A. Domperidone: A peripherally acting dopamine2-receptor antagonist. Ann. Pharmacother. 33, 429\u2013440. https:\/\/doi.org\/10.1345\/aph.18003 (1999).","journal-title":"Ann. Pharmacother."},{"key":"69053_CR2","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1111\/j.1572-0241.2007.01255.x","volume":"102","author":"SC Reddymasu","year":"2007","unstructured":"Reddymasu, S. C., Soykan, I. & McCallum, R. W. Domperidone: Review of pharmacology and clinical applications in gastroenterology. Am. J. Gastroenterol. 102, 2036\u20132045. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01255.x (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"69053_CR3","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/j.1572-0241.1999.00456.x","volume":"94","author":"D Patterson","year":"1999","unstructured":"Patterson, D., Abell, T., Rothstein, R., Koch, K. & Barnett, J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am. J. Gastroenterol. 94, 1230\u20131234. https:\/\/doi.org\/10.1111\/j.1572-0241.1999.00456.x (1999).","journal-title":"Am. J. Gastroenterol."},{"key":"69053_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1572-0241.2000.01721.x","volume":"95","author":"DL Dumitrascu","year":"2000","unstructured":"Dumitrascu, D. L. & Weinbeck, M. Domperidone versus metoclopramide in the treatment of diabetic gastroparesis. Am. J. Gastroenterol. 95, 316\u2013317. https:\/\/doi.org\/10.1111\/j.1572-0241.2000.01721.x (2000).","journal-title":"Am. J. Gastroenterol."},{"key":"69053_CR5","doi-asserted-by":"publisher","first-page":"e13302","DOI":"10.1111\/nmo.13302","volume":"30","author":"JR Giudicessi","year":"2018","unstructured":"Giudicessi, J. R., Ackerman, M. J. & Camilleri, M. Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. Neurogastroenterol. Motil. 30, e13302. https:\/\/doi.org\/10.1111\/nmo.13302 (2018).","journal-title":"Neurogastroenterol. Motil."},{"key":"69053_CR6","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/s0140-6736(84)90841-9","volume":"2","author":"G Giaccone","year":"1984","unstructured":"Giaccone, G., Bertetto, O. & Calciati, A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet 2, 1336\u20131337. https:\/\/doi.org\/10.1016\/s0140-6736(84)90841-9 (1984).","journal-title":"Lancet"},{"key":"69053_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/s0140-6736(82)92016-5","volume":"1","author":"RA Joss","year":"1982","unstructured":"Joss, R. A., Goldhirsch, A., Brunner, K. W. & Galeazzi, R. L. Sudden death in cancer patient on high-dose domperidone. Lancet 1, 1019. https:\/\/doi.org\/10.1016\/s0140-6736(82)92016-5 (1982).","journal-title":"Lancet"},{"key":"69053_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s0140-6736(85)92515-2","volume":"2","author":"RJ Osborne","year":"1985","unstructured":"Osborne, R. J., Slevin, M. L., Hunter, R. W. & Hamer, J. Cardiotoxicity of intravenous domperidone. Lancet 2, 385. https:\/\/doi.org\/10.1016\/s0140-6736(85)92515-2 (1985).","journal-title":"Lancet"},{"key":"69053_CR9","doi-asserted-by":"publisher","unstructured":"Roussak, J. B., Carey, P. & Parry, H. Cardiac arrest after treatment with intravenous domperidone. Br. Med. J. (Clin. Res. Ed) 289, 1579, https:\/\/doi.org\/10.1136\/bmj.289.6458.1579 (1984).","DOI":"10.1136\/bmj.289.6458.1579"},{"key":"69053_CR10","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s40264-015-0338-0","volume":"38","author":"A Arana","year":"2015","unstructured":"Arana, A. et al. Risk of out-of-hospital sudden cardiac death in users of domperidone, proton pump inhibitors, or metoclopramide: A population-based nested case-control study. Drug Saf. 38, 1187\u20131199. https:\/\/doi.org\/10.1007\/s40264-015-0338-0 (2015).","journal-title":"Drug Saf."},{"key":"69053_CR11","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1093\/eurheartj\/ehi312","volume":"26","author":"SM Straus","year":"2005","unstructured":"Straus, S. M. et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur. Heart J. 26, 2007\u20132012. https:\/\/doi.org\/10.1093\/eurheartj\/ehi312 (2005).","journal-title":"Eur. Heart J."},{"key":"69053_CR12","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2165\/11536840-000000000-00000","volume":"33","author":"C van Noord","year":"2010","unstructured":"van Noord, C., Dieleman, J. P., van Herpen, G., Verhamme, K. & Sturkenboom, M. C. Domperidone and ventricular arrhythmia or sudden cardiac death: A population-based case-control study in the Netherlands. Drug Saf. 33, 1003\u20131014. https:\/\/doi.org\/10.2165\/11536840-000000000-00000 (2010).","journal-title":"Drug Saf."},{"key":"69053_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/pds.3814","volume":"24","author":"HL Chen","year":"2015","unstructured":"Chen, H. L. & Hsiao, F. Y. Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: A nationwide case-crossover study. Pharmacoepidemiol. Drug Saf. 24, 841\u2013848. https:\/\/doi.org\/10.1002\/pds.3814 (2015).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"69053_CR14","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/pds.2016","volume":"19","author":"CB Johannes","year":"2010","unstructured":"Johannes, C. B., Varas-Lorenzo, C., McQuay, L. J., Midkiff, K. D. & Fife, D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: A nested case-control study. Pharmacoepidemiol. Drug Saf. 19, 881\u2013888. https:\/\/doi.org\/10.1002\/pds.2016 (2010).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"69053_CR15","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1177\/2050640618799153","volume":"6","author":"S Bor","year":"2018","unstructured":"Bor, S., Demir, M., Ozdemir, O. & Yuksel, K. A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide. United Eur. Gastroenterol. J. 6, 1331\u20131346. https:\/\/doi.org\/10.1177\/2050640618799153 (2018).","journal-title":"United Eur. Gastroenterol. J."},{"key":"69053_CR16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/MCG.0000000000001183","volume":"53","author":"J Field","year":"2019","unstructured":"Field, J. et al. Effect of chronic domperidone use on QT interval: A large single center study. J. Clin. Gastroenterol. 53, 648\u2013652. https:\/\/doi.org\/10.1097\/MCG.0000000000001183 (2019).","journal-title":"J. Clin. Gastroenterol."},{"key":"69053_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/cpdd.126","volume":"4","author":"J Biewenga","year":"2015","unstructured":"Biewenga, J. et al. Absence of QTc prolongation with domperidone: A randomized, double-blind, placebo- and positive-controlled thorough QT\/QTc study in healthy volunteers. Clin. Pharmacol. Drug Dev. 4, 41\u201348. https:\/\/doi.org\/10.1002\/cpdd.126 (2015).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"69053_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","volume":"153","author":"MF Vaezi","year":"2017","unstructured":"Vaezi, M. F., Yang, Y. X. & Howden, C. W. Complications of proton pump inhibitor therapy. Gastroenterology 153, 35\u201348. https:\/\/doi.org\/10.1053\/j.gastro.2017.04.047 (2017).","journal-title":"Gastroenterology"},{"key":"69053_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/AOG.0b013e31826af61a","volume":"120","author":"DA Grimes","year":"2012","unstructured":"Grimes, D. A. & Schulz, K. F. False alarms and pseudo-epidemics: The limitations of observational epidemiology. Obstet. Gynecol. 120, 920\u2013927. https:\/\/doi.org\/10.1097\/AOG.0b013e31826af61a (2012).","journal-title":"Obstet. Gynecol."},{"key":"69053_CR20","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.3748\/wjg.v18.i48.7371","volume":"18","author":"X Huang","year":"2012","unstructured":"Huang, X., Lv, B., Zhang, S., Fan, Y. H. & Meng, L. N. Itopride therapy for functional dyspepsia: A meta-analysis. World J. Gastroenterol. 18, 7371\u20137377. https:\/\/doi.org\/10.3748\/wjg.v18.i48.7371 (2012).","journal-title":"World J. Gastroenterol."},{"key":"69053_CR21","first-page":"66","volume":"128","author":"PJ Buffery","year":"2015","unstructured":"Buffery, P. J. & Strother, R. M. Domperidone safety: A mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. N. Z. Med. J. 128, 66\u201374 (2015).","journal-title":"N. Z. Med. J."},{"key":"69053_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40261-015-0360-0","volume":"36","author":"N Leelakanok","year":"2016","unstructured":"Leelakanok, N., Holcombe, A. & Schweizer, M. L. Domperidone and risk of ventricular arrhythmia and cardiac death: A systematic review and meta-analysis. Clin. Drug Investig. 36, 97\u2013107. https:\/\/doi.org\/10.1007\/s40261-015-0360-0 (2016).","journal-title":"Clin. Drug Investig."},{"key":"69053_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/MAJ.0000000000000439","volume":"349","author":"A Ortiz","year":"2015","unstructured":"Ortiz, A. et al. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am. J. Med. Sci. 349, 421\u2013424. https:\/\/doi.org\/10.1097\/MAJ.0000000000000439 (2015).","journal-title":"Am. J. Med. Sci."},{"key":"69053_CR24","doi-asserted-by":"publisher","first-page":"i4515","DOI":"10.1136\/bmj.i4515","volume":"354","author":"I Petersen","year":"2016","unstructured":"Petersen, I., Douglas, I. & Whitaker, H. Self controlled case series methods: An alternative to standard epidemiological study designs. BMJ 354, i4515. https:\/\/doi.org\/10.1136\/bmj.i4515 (2016).","journal-title":"BMJ"},{"key":"69053_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000083234","volume":"74","author":"S Claassen","year":"2005","unstructured":"Claassen, S. & Zunkler, B. J. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology 74, 31\u201336. https:\/\/doi.org\/10.1159\/000083234 (2005).","journal-title":"Pharmacology"},{"key":"69053_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/FJC.0b013e31827afd0d","volume":"61","author":"LM Hondeghem","year":"2013","unstructured":"Hondeghem, L. M. Domperidone: Limited benefits with significant risk for sudden cardiac death. J. Cardiovasc. Pharmacol. 61, 218\u2013225. https:\/\/doi.org\/10.1097\/FJC.0b013e31827afd0d (2013).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"69053_CR27","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/00498250400015301","volume":"34","author":"C Simard","year":"2004","unstructured":"Simard, C. et al. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 34, 1013\u20131023. https:\/\/doi.org\/10.1080\/00498250400015301 (2004).","journal-title":"Xenobiotica"},{"key":"69053_CR28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1124\/pr.58.2.7","volume":"58","author":"L Couture","year":"2006","unstructured":"Couture, L., Nash, J. A. & Turgeon, J. The ATP-binding cassette transporters and their implication in drug disposition: A special look at the heart. Pharmacol. Rev. 58, 244\u2013258. https:\/\/doi.org\/10.1124\/pr.58.2.7 (2006).","journal-title":"Pharmacol. Rev."},{"key":"69053_CR29","doi-asserted-by":"publisher","first-page":"e15666","DOI":"10.1371\/journal.pone.0015666","volume":"5","author":"V Michaud","year":"2010","unstructured":"Michaud, V., Frappier, M., Dumas, M. C. & Turgeon, J. Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS ONE 5, e15666. https:\/\/doi.org\/10.1371\/journal.pone.0015666 (2010).","journal-title":"PLoS ONE"},{"key":"69053_CR30","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/ije\/dyv319","volume":"46","author":"J Lee","year":"2017","unstructured":"Lee, J., Lee, J. S., Park, S. H., Shin, S. A. & Kim, K. Cohort profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int. J. Epidemiol. 46, e15. https:\/\/doi.org\/10.1093\/ije\/dyv319 (2017).","journal-title":"Int. J. Epidemiol."},{"key":"69053_CR31","doi-asserted-by":"crossref","unstructured":"Farrington, P., Whitaker, H. & Weldeselassie, Y. G. Self-Controlled Case Series Studies: A Modelling Guide with R. (Chapman and Hall\/CRC, 2018).","DOI":"10.1201\/9780429491313"},{"key":"69053_CR32","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, 2018). https:\/\/www.R-project.org\/. Accessed 1 May 2019."},{"key":"69053_CR33","unstructured":"Turner, H. & Firth, D. Generalized Nonlinear Models in R: An Overview of the gnm Package (2007). https:\/\/cran.r-project.org\/web\/packages\/gnm\/...\/gnmOverview.pdf . Accessed 1 May 2019."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69053-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69053-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69053-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:36:34Z","timestamp":1670337394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69053-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69053"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69053-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"30 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12158"}}